Short Communication: Focal encephalitis related to viral escape and resistance emergence in cerebrospinal fluid in a patient on lopinavir/ritonavir monotherapy with plasma HIV-1 RNA suppression

AIDS Research and Human Retroviruses

Volumn 30, Issue 10, 2014, Pages 984-987

  Imaz, Arkaitz ^a   Cayuela, Nuria ^a   Niubó, Jordi ^a   Tiraboschi, Juan Manuel ^a   Izquierdo, Cristina ^a   Cabellos, Carmen ^a   Podzamczer, Daniel ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ACICLOVIR; AMPICILLIN; CITALOPRAM; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETIRACETAM; GADOLINIUM; LAMIVUDINE PLUS LOPINAVIR PLUS RITONAVIR; LAMIVUDINE PLUS STAVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; OXCARBAZEPINE; RALTEGRAVIR; RITONAVIR; TENOFOVIR; VIRUS RNA; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CASE REPORT; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID; CLINICAL FEATURE; CONTRAST ENHANCEMENT; DEPRESSION; DIFFUSION WEIGHTED IMAGING; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; EPILEPTIC STATE; FEMALE; FEVER; FOCAL ENCEPHALITIS; GENE REPRESSION; GENOTYPE; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LEUKOCYTE COUNT; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; LIVER FIBROSIS; LUMBAR PUNCTURE; MEDICATION COMPLIANCE; MIXED INFECTION; MONOTHERAPY; MOTOR DYSFUNCTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARALYSIS; PARESTHESIA; PARIETAL LOBE; PERIPHERAL BLOOD MONONUCLEAR CELL; PNEUMOCYSTIS PNEUMONIA; SALVAGE THERAPY; TANDEM MASS SPECTROMETRY; TONIC CLONIC SEIZURE; VIRUS ENCEPHALITIS; VIRUS ENTRY; VIRUS LOAD; VIRUS REPLICATION; WHITE MATTER; COMPLICATION; HIV INFECTIONS; VIROLOGY;

ADULT; ENCEPHALITIS, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LOPINAVIR; RITONAVIR;

EID: 84907538945     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2014.0014     Document Type: Article

References (26)

1. Sacktor N, Lyles RH, Skolasky R, et al.: HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 2001;56:257-260.
2. Antinori A, Arendt G, Becker JT, et al.: Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007;69:1789-1799.
3. Robertson KR, Smurzynski M, Parsons TD, et al.: The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007;21:1915-1921.
4. Simioni S, Cavassini M, Annoni JM, et al.: Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010;24:1243-1250.
5. Letendre S, Marquie-Beck J, Capparelli E, et al.: CHARTER Group: Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008;65:65-70.
6. Smurzynski M, Wu K, Letendre S, et al.: Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 2011;25:357-365.
7. Cusini A, Vernazza PL, Yerly S, et al.: Swiss HIV Cohort Study: Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. J Acquir Immune Defic Syndr 2013;62:28-35.
8. Venturi G, Catucci M, Romano L, et al.: Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples. J Infect Dis 2000;181:740-745.
9. Canestri A, Lescure FX, Jaureguiberry S, et al.: Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 2010;50:773-778.
10. Peluso MJ, Ferretti F, Peterson J, et al.: Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS 2012;26:1765-1774.
11. Lescure FX, Moulignier A, Savatovsky J, et al.: CD8 encephalitis in HIV-infected patients receiving cART: A treatable entity. Clin Infect Dis 2013;57:101-108.
12. Pulido F, Arribas JR, Delgado R, et al.: OK04 Study Group: Lopinavir-ritonavir monotherapy versus lopinavirritonavir and two nucleosides for maintenance therapy of HIV. AIDS 2008;22:F1-9.
13. Arribas JR, Horban A, Gerstoft J, et al.: The MONET trial: Darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 2010;24:223-230.
14. Katlama C, Valantin MA, Algarte-Genin M, et al.: Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: A randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010;24: 2365-2374.
15. Arribas JR, Doroana M, Turner D, et al.: Boosted protease inhibitor monotherapy in HIV-infected adults: Outputs from a pan-European expert panel meeting. AIDS Res Ther 2013;10:3.
16. Capparelli EV, Holland D, Okamoto C, et al.: HNRC Group: Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS 2005; 19:949-952.
17. Calcagno A, Yilmaz A, Cusato J, et al.: Determinants of darunavir cerebrospinal fluid concentrations: Impact of once-daily dosing and pharmacogenetics. AIDS 2012;26:1529-1533.
18. Gutmann C, Cusini A, Gunthard HF, et al.: Swiss HIV Cohort Study (SHCS): Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: The role of compartment and CD4-nadir. AIDS 2010;24:2347-2354.
19. Bierhoff M, Boucher CA, Fibriani A, et al.: Ongoing HIV replication in cerebrospinal fluid under successful monotherapy. Antivir Ther 2013;18:641-643.
20. Perez-Valero I, Bayon C, Cambron I, et al.: Protease inhibitor monotherapy and the CNS: Peace of mind? J Antimicrob Chemother 2011;66:1954-1962.
21. Letendre SL, Ellis RJ, Ances BM, et al.: Neurologic complications of HIV disease and their treatment. Top HIV Med 2010;18:45-55.
22. Kleines M, Schiefer J, Stienen A, et al.: Expanding the spectrum of neurological disease associated with Epstein- Barr virus activity. Eur J Clin Microbiol Infect Dis 2011;30: 1561-1569.
23. European AIDS Clinical Society (EACS) Guidelines: Clinical management and treatment of HIV infected adults in Europe. Version 7.0, October 2013. Available at www.europeanaidsclinicalsociety.org/. Accessed December 17, 2013.
24. Perez-Valero I, Gonzalez-Baeza A, Estebanez M, et al.: Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy. PLoS One 2013;8(7):e69493.
25. Santos JR, Munoz-Moreno JA, Molto J, et al.: Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: An exploratory study. PLoS One 2013;8:e70201.
26. Castagna A, Danise A, Menzo S, et al.: Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudineresistant virus: A randomized pilot study (E-184V study). AIDS 2006;20:795-803.